Novartis is closing the doors to its gene therapy manufacturing plant in Libertyville, Illinois following a manufacturing site network evaluation. According to Novartis, the reshape of the company will mean that operations concerning the production of Zolgensma (onasemnogene abeparvovec), a one-time spinal muscular atrophy (SMA) gene therapy — approved in the US in May 2019 –  will be consolidated to its Durham, North Carolina facility. “Following a comprehensive manufacturing site network evaluation, Novartis has made the difficult decision to cease operations at…